Northern Trust Corp Boosts Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Northern Trust Corp lifted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 14.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 437,833 shares of the company's stock after buying an additional 53,658 shares during the period. Northern Trust Corp owned approximately 0.68% of Kymera Therapeutics worth $17,614,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Blue Trust Inc. boosted its position in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after purchasing an additional 270 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after acquiring an additional 406 shares during the period. KBC Group NV increased its stake in Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after acquiring an additional 752 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Kymera Therapeutics by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company's stock valued at $552,000 after purchasing an additional 1,311 shares during the period. Finally, Arizona State Retirement System grew its stake in shares of Kymera Therapeutics by 15.5% in the 4th quarter. Arizona State Retirement System now owns 11,221 shares of the company's stock valued at $451,000 after purchasing an additional 1,503 shares during the period.

Insider Activity

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This represents a 3.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at $2,064,510. The trade was a 2.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,659 shares of company stock worth $324,567. Company insiders own 16.01% of the company's stock.

Analysts Set New Price Targets

KYMR has been the topic of several recent analyst reports. Guggenheim reissued a "buy" rating and issued a $52.00 target price on shares of Kymera Therapeutics in a report on Monday, May 12th. UBS Group lowered their price objective on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday. HC Wainwright increased their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Citigroup began coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $52.00 target price for the company. Finally, Bank of America cut their price objective on shares of Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating for the company in a research report on Monday, May 12th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $55.27.

Kymera Therapeutics Trading Up 0.8%

KYMR stock traded up $0.23 during midday trading on Friday, hitting $30.25. The stock had a trading volume of 440,383 shares, compared to its average volume of 561,963. The firm has a market cap of $1.97 billion, a P/E ratio of -12.93 and a beta of 2.18. Kymera Therapeutics, Inc. has a 1-year low of $19.45 and a 1-year high of $53.27. The business has a fifty day moving average price of $29.36 and a two-hundred day moving average price of $37.05.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. During the same quarter in the prior year, the business earned ($0.69) earnings per share. The business's quarterly revenue was up 114.6% compared to the same quarter last year. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.